The Cancer Center (CORE) Support Grant (CCSG), will provide the necessary financial support that will assure quality administration of major programs in interdisciplinary basic and clinical cancer research, cancer education and training, cancer diagnosis and therapy, and community outreach. It is the intent of the OSUCCC to translate its own and other laboratories' observations into applicable clinical usage and to communicate existing and newly developed therapies, diagnostic procedures and prevention methods to the Ohio Valley Region. The CCSG will provide salary support for directors of vital programs and for key investigators necessary for further Center development. These individuals will collectively help to: (1) Optimally utilize and integrate the cancer efforts extant within the seven colleges at OSU engaged in cancer research; (2) Develop new programs, pilot studies and demonstration projects in cancer research, education, diagnosis and therapy within the OSUCCC and at community levels; (3) Encourage, aid, support and integrate community-run programs which are aimed to meet the needs of the respective areas; (4) Develop interdisciplinary activities between clinical and basic scientists to affect the translation process from laboratory to clinical application; (5) Communicate approved new developments in cancer diagnosis, therapy and rehabilitation to cooperating institutions throughout the Ohio Valley Region; (6) Establish effective cooperation with other existing and developing cancer centers including the National Cancer Institute. The OSUCCC will undergo significant development during the next five years that should culminate in solidification of research programs and development of an effective Cancer Control program for the region.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-12
Application #
3101524
Study Section
(SRC)
Project Start
1977-07-01
Project End
1986-09-29
Budget Start
1985-07-01
Budget End
1986-09-29
Support Year
12
Fiscal Year
1985
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
Overall Medical
DUNS #
098987217
City
Columbus
State
OH
Country
United States
Zip Code
43210
Ozawa, Patricia Midori Murobushi; Alkhilaiwi, Faris; Cavalli, Iglenir João et al. (2018) Extracellular vesicles from triple-negative breast cancer cells promote proliferation and drug resistance in non-tumorigenic breast cells. Breast Cancer Res Treat 172:713-723
Ngankeu, Apollinaire; Ranganathan, Parvathi; Havelange, Violaine et al. (2018) Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia. Oncotarget 9:4354-4365
Lopez, Cecilia M; Yu, Peter Y; Zhang, Xiaoli et al. (2018) MiR-34a regulates the invasive capacity of canine osteosarcoma cell lines. PLoS One 13:e0190086
Victor, Aaron R; Weigel, Christoph; Scoville, Steven D et al. (2018) Epigenetic and Posttranscriptional Regulation of CD16 Expression during Human NK Cell Development. J Immunol 200:565-572
Lampis, Andrea; Carotenuto, Pietro; Vlachogiannis, Georgios et al. (2018) MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma. Gastroenterology 154:1066-1079.e5
Le Gallo, Matthieu; Rudd, Meghan L; Urick, Mary Ellen et al. (2018) The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas. Cancer 124:65-73
Jones, Jeffrey A; Mato, Anthony R; Wierda, William G et al. (2018) Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol 19:65-75
Baldassari, Federica; Zerbinati, Carlotta; Galasso, Marco et al. (2018) Screen for MicroRNA and Drug Interactions in Breast Cancer Cell Lines Points to miR-126 as a Modulator of CDK4/6 and PIK3CA Inhibitors. Front Genet 9:174
Yang, Xiaosong; Pan, You; Qiu, Zhaojun et al. (2018) RNF126 as a Biomarker of a Poor Prognosis in Invasive Breast Cancer and CHEK1 Inhibitor Efficacy in Breast Cancer Cells. Clin Cancer Res 24:1629-1643
Latchana, Nicholas; DiVincenzo, Mallory J; Regan, Kelly et al. (2018) Alterations in patient plasma microRNA expression profiles following resection of metastatic melanoma. J Surg Oncol 118:501-509

Showing the most recent 10 out of 2602 publications